2327 GMT [Dow Jones]--Cochlear's lineup of new products turns UBS analysts bullish on the stock. They upgrade their recommendation on the hearing-tech manufacturer to buy from neutral, telling clients in a note that they expect its new implant portfolio to deliver global market share gains and 10% compound annual revenue growth from implants over the next three years. They also see services revenue rising 40% over three years from a higher installed base and as customers replace processors. UBS raises its target price 14% to A$325.00. Shares are at A$281.66 ahead of the open. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
June 17, 2025 19:34 ET (23:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.